These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 23484454)

  • 1. The effect of estrogen on the sexual interest of castrated males: Implications to prostate cancer patients on androgen-deprivation therapy.
    Wibowo E; Wassersug RJ
    Crit Rev Oncol Hematol; 2013 Sep; 87(3):224-38. PubMed ID: 23484454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The health and well-being of prostate cancer patients and male-to-female transsexuals on androgen deprivation therapy: a qualitative study with comments on expectations and estrogen.
    Wassersug RJ; Gray R
    Psychol Health Med; 2011 Jan; 16(1):39-52. PubMed ID: 21218363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The sexuality and social performance of androgen-deprived (castrated) men throughout history: implications for modern day cancer patients.
    Aucoin MW; Wassersug RJ
    Soc Sci Med; 2006 Dec; 63(12):3162-73. PubMed ID: 16989928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parenteral estrogens for prostate cancer: can a new route of administration overcome old toxicities?
    Lycette JL; Bland LB; Garzotto M; Beer TM
    Clin Genitourin Cancer; 2006 Dec; 5(3):198-205. PubMed ID: 17239273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer.
    Scherr DS; Pitts WR
    J Urol; 2003 Nov; 170(5):1703-8. PubMed ID: 14532759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of testosterone suppression and recovery on sexual function in men with prostate cancer: observations from a prospective study in men undergoing intermittent androgen suppression.
    Ng E; Woo HH; Turner S; Leong E; Jackson M; Spry N
    J Urol; 2012 Jun; 187(6):2162-6. PubMed ID: 22503022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sexual healing in patients with prostate cancer on hormone therapy.
    Schover LR
    Am Soc Clin Oncol Educ Book; 2015; ():e562-6. PubMed ID: 25993223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of sexual and erectile dysfunction and response to treatment in patients receiving androgen deprivation therapy for prostate cancer.
    DiBlasio CJ; Malcolm JB; Derweesh IH; Womack JH; Kincade MC; Mancini JG; Ogles ML; Lamar KD; Patterson AL; Wake RW
    BJU Int; 2008 Jul; 102(1):39-43. PubMed ID: 18294309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does the timing of estrogen administration after castration affect its ability to preserve sexual interest in male rats?--exploring the critical period hypothesis.
    Wibowo E; Wassersug RJ
    Physiol Behav; 2013 Feb; 110-111():63-72. PubMed ID: 23274500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen deprivation therapy: evidence-based management of side effects.
    Ahmadi H; Daneshmand S
    BJU Int; 2013 Apr; 111(4):543-8. PubMed ID: 23351025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
    Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen deprivation therapy for advanced prostate cancer: why does it fail and can its effects be prolonged?
    Singer EA; Golijanin DJ; Messing EM
    Can J Urol; 2008 Dec; 15(6):4381-7. PubMed ID: 19046491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estrogen and estrogen-androgen replacement in postmenopausal women dissatisfied with estrogen-only therapy. Sexual behavior and neuroendocrine responses.
    Sarrel P; Dobay B; Wiita B
    J Reprod Med; 1998 Oct; 43(10):847-56. PubMed ID: 9800666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathologic effects of testosterone deprivation.
    Sprenkle PC; Fisch H
    Curr Opin Urol; 2007 Nov; 17(6):424-30. PubMed ID: 17921778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The perspective of prostate cancer patients and patients' partners on the psychological burden of androgen deprivation and the dyadic adjustment of prostate cancer couples.
    Hamilton LD; Van Dam D; Wassersug RJ
    Psychooncology; 2016 Jul; 25(7):823-31. PubMed ID: 26411285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contemporary use of hormonal therapy in prostate cancer: managing complications and addressing quality-of-life issues.
    Gomella LG
    BJU Int; 2007 Jan; 99 Suppl 1():25-9; discussion 30. PubMed ID: 17229166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of androgen deprivation therapy on quality of life in Japanese men with prostate cancer.
    Kato T; Komiya A; Suzuki H; Imamoto T; Ueda T; Ichikawa T
    Int J Urol; 2007 May; 14(5):416-21. PubMed ID: 17511724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endocrine prevention and treatment of prostate cancer.
    Tammela TL
    Mol Cell Endocrinol; 2012 Sep; 360(1-2):59-67. PubMed ID: 22465099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The timing and extent of androgen deprivation therapy for prostate cancer: weighing the clinical evidence.
    Ginzburg S; Albertsen PC
    Endocrinol Metab Clin North Am; 2011 Sep; 40(3):615-23, ix. PubMed ID: 21889724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Life after failure of traditional androgen deprivation therapy.
    Schellhammer P
    Urol Oncol; 2012; 30(4 Suppl):S10-4. PubMed ID: 22795075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.